Drug Information

Drug (ID: DG01841) and It's Reported Resistant Information

Name	Rhodium trichloride hydrate
Synonyms	Rhodium trichloride hydrate; Rhodium(III) chloride xhydrate; CDDP;cis-Diaminodichloroplatinum; Cl3H2ORh; trichlororhodium hydrate; trichlororhodium;hydrate; rhodium chloride hydrate; rhodiumtrichloride hydrate; Rhodium(III) chloride 3-hydrate; BCP26055; 0627AB; AKOS015924295; Rhodium chloride (RhCl3), hydrate (9CI); Rhodium(III) chloride hydrate, Rh =>39%; Rhodium(III) chloride hydrate, Rh 38-40 %; A814863; trichlororhodium hydrate;Rhodium(III) Chloride Hydrate; Rhodium(III) chloride hydrate, 99.98% trace metals basis; Rhodium(III) chloride hydrate, Rh =>39% trace metal grade 99.99%; Rhodium(III) chloride hydrate, crystalline, >=99.9% trace metals basis Click to Show/Hide
Structure
Drug Resistance Disease(s)	Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (2 diseases) Bladder cancer [ICD-11: 2C94] [1] Gastric cancer [ICD-11: 2B72] [2]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
IsoSMILES	O.Cl[Rh](Cl)Cl
InChI	InChI=1S/3ClH.H2O.Rh/h3*1H;1H2;/q;;;;+3/p-3
InChIKey	HSSMNYDDDSNUKH-UHFFFAOYSA-K
PubChem CID	16211510
DrugBank ID	DB00515

Type(s) of Resistant Mechanism of This Drug

EADR: Epigenetic Alteration of DNA, RNA or Protein

MRAP: Metabolic Reprogramming via Altered Pathways

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Gastric cancer [ICD-11: 2B72]

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Key Molecule: Hepatocellular carcinoma up-regulated long non-coding RNA (HULC)				[2]
Resistant Disease	Gastric adenocarcinoma [ICD-11: 2B72.0]			Disease Info
Molecule Alteration	Up-regulation		Expression	Molecule Info
Experimental Note	Revealed Based on the Cell Line Data
In Vitro Model	MGC-803 cells	Gastric	Homo sapiens (Human)	CVCL_5334
	SGC7901 cells	Gastric	Homo sapiens (Human)	CVCL_0520
In Vivo Model	BALB/c nude mice model			Mus musculus
Experiment for Molecule Alteration	Western bloting analysis; qRT-PCR
Experiment for Drug Resistance	CCK8 assay
Mechanism Description	METase/LncRNA HULC/FoxM1 reduced cisplatin resistance in gastric cancer by suppressing autophagy.

Bladder cancer [ICD-11: 2C94]

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Metabolic Reprogramming via Altered Pathways (MRAP)		Click to Show/Hide
Key Molecule: Isocitrate dehydrogenase [NADP] mitochondrial (IDH2)			[1]
Metabolic Type	Glucose metabolism
Resistant Disease	Urothelial carcinoma [ICD-11: 2C94.2]		Disease Info
Molecule Alteration	Expression	Up-regulation	Molecule Info
Experimental Note	Revealed Based on the Cell Line Data
Cell Pathway Regulation	Adrenergic signaling in cardiomyocytes	Activation	hsa04261
In Vivo Model	BALB/c-nu/nu mice, with UMUC3GR cells		Mice
Experiment for Molecule Alteration	qRT-PCR; Western blot analysis
Experiment for Drug Resistance	Tumor volume assay
Mechanism Description	Furthermore, we observed that gain-of-function of isocitrate dehydrogenase 2 (IDH2) induced reductive glutamine metabolism to stabilize Hif-1alpha expression and consequently stimulate aerobic glycolysis and PPP bypass in gemcitabine-resistant UC cells. Interestingly, IDH2-mediated metabolic reprogramming also caused cross resistance to CDDP, by elevating the antioxidant defense via increased NADPH and glutathione production. Downregulation or pharmacological suppression of IDH2 restored chemosensitivity.

References

Ref 1	IDH2 stabilizes HIF-1alpha-induced metabolic reprogramming and promotes chemoresistance in urothelial cancer. EMBO J. 2023 Feb 15;42(4):e110620.
Ref 2	METase/lncRNA HULC/FoxM1 reduced cisplatin resistance in gastric cancer by suppressing autophagyJ Cancer Res Clin Oncol. 2019 Oct;145(10):2507-2517. doi: 10.1007/s00432-019-03015-w. Epub 2019 Sep 4.